At Kazia, we believe that the best thing we can do for our investors is to deliver high-quality science that makes a substantial impact on the lives of patients.
Kazia's pipeline assets are scientifically well-validated, and their early development has been performed to the highest possible standards of quality in large pharmaceutical companies.
The company has a track record of successful partnering, both inbound and outbound and has demonstrated the ability to realise value from its pipeline, even prior to product approval.
Kazia is a lean, agile business, in which broad clinical trial programs have been deployed with a very high level of cost efficiency, and which has shown a consistent ability to deliver on its objectives.
Kazia Therapeutics Limited
Three International Towers
Level 24, 300 Barangaroo Avenue
Sydney NSW 2000, Australia
Which of the following group do you best fit?
Subscribe to our Email Alerts